With EmeTerm(TM), Pregnant Women Don't Have to Suffer from Morning Sickness -- MEDICA - World Forum for Medicine


WAT Medical Enterprise Ltd.

With EmeTerm(TM), Pregnant Women Don't Have to Suffer from Morning Sickness

VANCOUVER, British Columbia,June 30, 2017/PRNewswire/  -- Morning sickness affects 70-80% of all pregnant women.About 60% of them experience nausea and vomiting. Morning sickness can decrease pregnant women's work efficiency, result in unnecessary healthcare expenses, and negatively impact the quality of life of both the mothers and the unborn children. Some women even choose to have an abortion due to the severity of the symptoms.

One of the worst drug disasters in history resulted from an attempt to cease morning sickness with medications. Thalidomide, sold under the name, Immunoprin, was an anti-morning sickness drug used in the 1950s. This resulted in about 10,000 cases of infants who were born with phocomelia (the underdevelopment or absent of limbs and vital organs); only 50% of the 10,000 infants survived. While many modern medications are used today with low risk factors, they often contain debilitating side-effects.

EmeTerm™ is a drug free, none-invasive, and precise neuronal electrical stimulation technology that prevents and relieves morning sickness. By releasing a particular low-frequency electrical pulse from the user's wrist, EmeTerm™ adjusts the vagus nerve signals traveling to and from the stomach. This prevents or postpones the brain from transmitting nausea signals to the stomach. This then slows down the nausea-inducing irregular gastric contraction, and reduces the nauseous sensation for the users.

Safety is the number one priority of EmeTerm™. All the materials of the device meet medical standards. EmeTerm™ uses medical silicone, instead of natural rubber, making the device hypoallergenic. Inert metal is used in electrodes to avoid skin irritation. The patented electrodes are parallel with tendon, which enhances the electric conduction and no conduction gel with potentially allergenic chemical compounds is needed.

EmeTerm is CE marked class II medical device.
EmeTerm is winner of iF Design Award 2017. 
The manufacturer,WAT Medical Enterprise Ltd., is certified to the ISO 13485 medical standard.

For more information, please visit WAT Medical Enterprise Ltd.'s website at www.watmedical.com or email info@watmedical.com.


al-Sadi M, Newman B, Julious SA. Acupuncture in the prevention of postoperative nausea and vomiting. Anaesthesia. 1997 Jul;52(7):658-61.

ates BJ, Miller AD, Lucot JB. Physiological basis and pharmacology of motion sickness: an update. Brain Res Bull. 1998 Nov 15;47(5):395-406.

Takahashi T. Acupuncture for functional gastrointestinal disorders. J Gastroenterol. 2006 May;41(5):408-17.

Streitberger K, Ezzo J, Schneider A. Acupuncture for nausea and vomiting: an update of clinical and experimental studies. Auton Neurosci. 2006 Oct 30;129(1-2):107-17.

Schmäl F. Neuronal mechanisms and the treatment of motion sickness. Pharmacology. 2013;91(3-4):229-41.

Exhibitor Data Sheet